Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis

Circulation

Volumn 106, Issue 17, 2002, Pages 2184-2187

  Hürlimann, David ^a   Forster, Adrian ^a   Noll, Georg ^a   Enseleit, Frank ^a   Chenevard, Rémy ^a   Distler, Oliver ^a   Béchir, Markus ^a   Spieker, Lukas E ^a   Neidhart, Michel ^a   Michel, Beat A ^a   Gay, Renate E ^a   Lüscher, Thomas F ^a   Gay, Steffen ^a   Ruschitzka, Frank ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Atherosclerosis; Endothelium; Inflammation; Risk factors

Indexed keywords

C REACTIVE PROTEIN; CELL ADHESION MOLECULE; GLYCERYL TRINITRATE; INFLIXIMAB; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTHRITIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENDOTHELIUM LESION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNE RESPONSE; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; VASCULAR DISEASE; VASODILATATION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BRACHIAL ARTERY; C-REACTIVE PROTEIN; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; VASODILATION;

EID: 0037159293     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000037521.71373.44     Document Type: Article

References (26)

1. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med. 1999;340:115-126.
2. Pasceri V, Yeh ET. A tale of two diseases: Atherosclerosis and rheumatoid arthritis. Circulation. 1999;100:2124-2126.
3. van der Wal AC, Becker AE, van der Loos CM, et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36-44.
4. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001;89:763-771.
5. Feldmann M, Brennan FM, Foxwell BM, et al. The role of TNF alpha and IL-1 in rheumatoid arthritis. Curr Dir Autoimmun. 2001;3:188-199.
6. Lipsky PE, van der Heijde DM, St Clair EW, et al. for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594-1602.
7. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
8. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-48.
9. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137-145.
10. Bruhlmann P, Stucki G, Michel BA. Evaluation of a German version of the physical dimensions of the Health Assessment Questionnaire in patients with rheumatoid arthritis. J Rheumatol. 1994;21:1245-1249.
11. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111-1115.
12. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995;91:1314-1319.
13. Mutru O, Laakso M, Isomaki H, et al. Cardiovascular mortality in patients with rheumatoid arthritis. Cardiology. 1989;76:71-77.
14. Choi HK, Hernan MA, Seeger JD, et al, Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. Lancet. 2002;359:1173-1177.
15. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101:1899-1906.
16. Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 2001;104:191-196.
17. Skoog T, Dichtl W, Boquist S, et al. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J. 2002;23:376-383.
18. Ferro D, Pittoni V, Quintarelli C, et al. Coexistence of anti-phospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state. Circulation. 1997;95:1425-1432.
19. Lima DS, Sato El, Lima VC, et al. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol. 2002;29:292-297.
20. Wang P, Ba ZF, Chaudry IH. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol. 1994;266:H2535-H2541.
21. Fichtlscherer S, Rossig L, Breuer S, et al. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation. 2001;104:3023-3025.
22. Glosli H, Tronstad KJ, Wergedal H, et al. Human TNF-α in transgenic mice induces differential changes in redox status and glutathione-regulating enzymes. FASEB J. 2002;16:1450-1452.
23. Hermann C, Assmus B, Urbich C, et al. Insulin-mediated stimulation of protein kinase Akt: A potent survival signaling cascade for endothelial cells. Arterioscler Thromb Vasc Biol. 2000;20:402-409.
24. Dimmeler S, Fleming I, Fisslthaler B, et al, Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601-605.
25. Yoshizumi M, Perrella MA, Burnett JC Jr, et al. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res. 1993;73:205-209.
26. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med. 2002;347:185-192.